BusinessElite Pharmaceuticals Reports Positive Topline Results from SequestOx™ Pilot StudyBy Nasdaq OMXJan 30, 2018, 1:36 PM UTC
BusinessElite Pharmaceuticals Reports Positive Topline Results from Pivotal Bioequivalence Studies for an Extended-Release GenericBy Nasdaq OMXJan 10, 2018, 1:02 PM UTC
BusinessElite Pharmaceuticals Announces FDA Approval of Phendimetrazine Tartrate Tablets USPBy Nasdaq OMXJan 2, 2018, 5:56 PM UTC
BusinessElite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2018 Ended September 30, 2017By Nasdaq OMXNov 9, 2017, 9:59 PM UTC
BusinessElite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2018 Ended June 30, 2017 and Provides Conference Call InformationBy Nasdaq OMXAug 9, 2017, 8:39 PM UTC
BusinessElite Announces Co-Development of Four Additional Products with SunGen PharmaBy Nasdaq OMXJul 28, 2017, 12:00 PM UTC
BusinessElite Announces New Development and License Agreement with SunGen Pharma LLCBy Nasdaq OMXJul 12, 2017, 12:32 PM UTC
BusinessElite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence StudyBy Nasdaq OMXMay 30, 2017, 12:57 PM UTC
